Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. for potential violations of federal securities laws after the company's Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint.
February 24, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations following the failure of its SPN-820 study to meet primary endpoints.
The failure of the SPN-820 study to meet its primary endpoint is a significant setback for Supernus Pharmaceuticals, potentially affecting its stock price negatively. The investigation by Levi & Korsinsky adds legal pressure, which could further impact investor confidence and the company's market value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100